The potential of quinoline derivatives for the treatment of Toxoplasma gondii infection

Experimental Parasitology

Volumn 145, Issue 1, 2014, Pages 135-144

  Kadri, Dema ^a   Crater, Anna K ^a   Lee, Hoyun ^b,c   Solomon, V Raja ^b   Ananvoranich, Sirinart ^a  

^a UNIVERSITY OF WINDSOR   (Canada)

^b Tumour Biology Group Advanced Medical Research Institute of Canada Northeast Cancer Centre Health Sciences North ^*  (Canada)

^c NORTHERN ONTARIO SCHOOL OF MEDICINE   (Canada)

Author keywords

Apicoplast; Quinoline derivatives; Toxoplasma gondii

Indexed keywords

8 QUINOLINOL; CHLOROQUINE; QUINOLINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLINE DERIVATIVE;

ANTIPROTOZOAL ACTIVITY; APICOPLAST; ARTICLE; DRUG CYTOTOXICITY; DRUG REPOSITIONING; DRUG STRUCTURE; DRUG SYNTHESIS; GROWTH INHIBITION; IC 50; NONHUMAN; PRIORITY JOURNAL; TOXOPLASMA GONDII; CELL CULTURE; CHEMISTRY; DRUG EFFECTS; FIBROBLAST; GROWTH, DEVELOPMENT AND AGING; HUMAN; IC50; PARASITOLOGY; TOXOPLASMA; TOXOPLASMOSIS; HUMAN CELL;

CELLS, CULTURED; FIBROBLASTS; HUMANS; INHIBITORY CONCENTRATION 50; QUINOLINES; TOXOPLASMA; TOXOPLASMOSIS;

EID: 84908458930     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2014.08.008     Document Type: Article

References (33)

1. Bessoff K., Spangenberg T., Foderaro J.E., Jumani R.S., Ward G.E., Huston C.D. Identification of Cryptosporidium parvum active chemical series by repurposing the open access malaria box. Antimicrob. Agents Chemother. 2014, 58:2731-2739.
2. Brockman R.W., Thomson J.R., Bell M.J., Skipper H.E. Observations on the antileukemic activity of pyridine-2-carboxaldehyde thiosemicarbazone and thiocarbohydrazone. Cancer Res. 1956, 16:167-170.
3. Butler A.R., Khan S., Ferguson E. A brief history of malaria chemotherapy. J. R. Coll. Physicians Edinb. 2010, 40:172-177.
4. Chong C.R., Sullivan D.J. New uses for old drugs. Nature 2007, 448:645-646.
5. Fichera M.E., Roos D.S. A plastid organelle as a drug target in apicomplexan parasites. Nature 1997, 390:407-409.
6. Foley M., Tilley L. Quinoline antimalarials: mechanisms of action and resistance and prospects for new agents. Pharmacol. Ther. 1998, 79:55-87.
7. Gershon H., Grefig A.T., Cady D.J. Evidence that the mechanisms of fungitoxicity of 8-quinolinol and its bischelate with copper(II) are different. Can. J. Microbiol. 1985, 31:707-710.
8. Hu C., Solomon V., Cano P., Lee H. A 4-aminoquinoline derivative that markedly sensitizes tumor cell killing by Akt inhibitors with a minimum cytotoxicity to non-cancer cells. Eur. J. Med. Chem. 2010, 45:705-709.
9. Jones-Brando L., Torrey E.F., Yolken R. Drugs used in the treatment of schizophrenia and bipolar disorder inhibit the replication of Toxoplasma gondii. Schizophr. Res. 2003, 62:237-244.
10. Katzer F., Lizundia R., Ngugi D., Blake D., McKeever D. Construction of a genetic map for Theileria parva: identification of hotspots of recombination. Int. J. Parasitol. 2011, 41:669-675.
11. Krivogorsky B., Grundt P., Yolken R., Jones-Brando L. Inhibition of Toxoplasma gondii by indirubin and tryptanthrin analogs. Antimicrob. Agents Chemother. 2008, 52:4466-4469.
12. McDonald J.H. Handbook of Biological Statistics 2008, 115-117. Sparky House Publishing, Baltimore, Maryland, USA.
13. McFadden D.C., Seeber F., Boothroyd J.C. Use of Toxoplasma gondii expressing beta-galactosidase for colorimetric assessment of drug activity in vitro. Antimicrob. Agents Chemother. 1997, 41:1849-1853.
14. Meunier B. Hybrid molecules with a dual mode of action: dream or reality. Acc. Chem. Res. 2007, 41:69-77.
15. Montoya J.G., Rosso F. Diagnosis and management of toxoplasmosis. Clin. Perinatol. 2005, 32:705-726.
16. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxic assays. J. Immunol. Methods 1983, 65:55-63.
17. Paloque L., Verhaeghe P., Casanova M., Castera-Ducros C., Dumetre A., Mbatchi L., Hutter S., Kraiem-M'rabet M., Laget M., Remusat V., Rault S., Rathelo P., Azas N., Vanelle P. Discovery of a new antileishmanial hit in 8-nitroquinoline series. Eur. J. Med. Chem. 2012, 54:75-86.
18. Peters P.J., Thigpen M.C., Parise M.E., Newman R.D. Safety and toxicity of sulfadoxine/pyrimethamine: implications for malaria prevention in pregnancy using intermittent preventive treatment. Drug Saf. 2007, 30:481-501.
19. Reed L.J., Muench H. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 1938, 27:493-499.
20. Scheibel L.W., Adler A. Antimalarial activity of selected aromatic chelators. III. 8-Hydroxyquinolines (oxines) substituted in positions 5 and 7, and oxines annelated in position 5,6 by an aromatic ring. Mol. Pharmacol. 1982, 22:140-144.
21. Seeber F., Boothroyd J.C. Escherichia coli beta-galactosidase as an in vitro and in vivo reporter enzyme and stable transfection marker in the intracellular protozoan parasite Toxoplasma gondii. Gene 1996, 169:39-45.
22. Sheiner L., Vaidya A.B., McFadden G.I. The metabolic roles of the endosymbiotic organelles of Toxoplasma and Plasmodium spp. Curr. Opin. Microbiol. 2013, 16:452-458.
23. Shen A.Y., Chen C.P., Roffler S. A chelating agent possessing cytotoxicity and antimicrobial activity: 7-morpholinomethyl-8-hydroxyquinoline. Life Sci. 1999, 64:813-825.
24. Shirley M.W., Harvey D.A. A genetic linkage map of the apicomplexan protozoan parasite Eimeria tenella. Genome Res. 2000, 10:1587-1593.
25. Slater A.F.G. Malaria pigment. Exp. Parasitol. 1992, 74:362-365.
26. Smith A.T., Livingston M.R., Mai A., Filetici P., Queener S.F., Sullivan W.J. Quinoline derivative MC1626, a putative GCN5 histone acetyltransferase (HAT) inhibitor, exhibits HAT-independent activity against Toxoplasma gondii. Antimicrob. Agents Chemother. 2007, 51:1109-1111.
27. Solomon V.R., Lee H. Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies. Eur. J. Pharmacol. 2009, 625:220-233.
28. Solomon V.R., Hu C., Lee H. Hybrid pharmacophore design and synthesis of isatin-benzothiazole analogs for their anti-breast cancer activity. Bioorg. Med. Chem. 2009, 17:7585-7592.
29. Solomon V.R., Hu C.K., Lee H. Design and synthesis of anti-breast cancer agents from 4-piperazinylquinoline: a hybrid pharmacophore approach. Bioorg. Med. Chem. 2010, 18:1563-1572.
30. Solomon V.R., Hu C.K., Lee H. Design and synthesis of chloroquine analogs with anti-breast cancer property. Eur. J. Med. Chem. 2010, 45:3916-3923.
31. Tenório R.P., Carvalho C.S., Pessanha C.S., de Lima J.G., de Faria A.R., et al. Synthesis of thiosemicarbazone and 4-thiazolidinone derivatives and their in vitro anti-Toxoplasma gondii activity. Bioorg. Med. Chem. Lett. 2005, 15:2575-2578.
32. Tzipori S., Ward H. Cryptosporidiosis: biology, pathogenesis and disease. Microbes Infect. 2002, 4:1047-1058.
33. Vannier E., Krause P.J. Update on babesiosis. Interdiscip. Perspect. Infect. Dis. 2009, 2009:1-9.